Journal of the American College of Cardiology
Original InvestigationLow-Density Lipoprotein Cholesterol and Adverse Cardiovascular Events After Percutaneous Coronary Intervention
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
This study was funded by a Foundation grant (FDN-154333) from the Canadian Institutes of Health Research. This study was supported by the ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care. The analyses, conclusions, opinions and statements expressed herein are solely those of the authors and do not reflect those of the funding or data sources. No endorsement by ICES, or the Ontario Ministry of Health and Long-Term Care is intended or should be inferred. Dr. Sud is funded by the Eliot Phillipson Clinician-Scientist Program at the University of Toronto and by a Canadian Institute of Health Research Post-Doctoral Fellowship. Dr. Abdel-Qadir has received consultant fees from Amgen; and has received fees for endpoint adjudication committee membership for the THEMIS trial funded by AstraZeneca research grants. Drs. Austin and Ko are supported by Mid-Career Investigator Awards from the Heart and Stroke Foundation, Ontario Provincial Office. Dr. Farkouh has received research grants from Amgen, Novartis, and NovoNordisk. Dr. Udell has received consulting or speaker honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, Janssen, Merck, Novartis, and Sanofi; and has received research grants to his institution from AstraZeneca, Novartis, and Sanofi. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC author instructions page.